Fig. 4

Multivariate analyses of associations with clinical outcomes in mCRPC patients. Risk groups were defined according to CTC counts and NLR values (A for PFS analysis and B for OS analysis), or defined according to CTC counts and PLR values (C for PFS analysis and D for OS analysis). Covariates applied in the model for PFS included chemotherapy after blood draw (yes vs. low), PSA (high vs. low), and ALP (high vs. low). For the OS model, the following covariates were also applied: ECOG performance status (1 vs. 0, ≥2 vs. 0), previous chemotherapy (yes vs. no), and ARSi after blood draw (yes vs. no). mCRPC: metastatic castration-resistant prostate cancer; ARSi: androgen receptor signaling inhibitor; CTC: circulating tumor cell; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; PSA: prostate-specific antigen; ALP: alkaline phosphatase; PFS: progression-free survival; OS: overall survival; HR, hazard ratio; CI: confidence interval